0001628280-19-015076.txt : 20191213 0001628280-19-015076.hdr.sgml : 20191213 20191213161208 ACCESSION NUMBER: 0001628280-19-015076 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191213 FILED AS OF DATE: 20191213 DATE AS OF CHANGE: 20191213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Maslowski John Michael CENTRAL INDEX KEY: 0001608774 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31564 FILM NUMBER: 191284737 MAIL ADDRESS: STREET 1: 404 EAGLEVIEW BOULEVARD CITY: EXTON STATE: PA ZIP: 19341 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Fibrocell Science, Inc. CENTRAL INDEX KEY: 0000357097 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870458888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 405 EAGLEVIEW BOULEVARD CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 484-713-6000 MAIL ADDRESS: STREET 1: 405 EAGLEVIEW BOULEVARD CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: ISOLAGEN INC DATE OF NAME CHANGE: 20020320 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN FINANCIAL HOLDING INC /DE DATE OF NAME CHANGE: 19960330 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN FINANCIAL HOLDING INC /CO DATE OF NAME CHANGE: 19921008 4 1 wf-form4_157627151073429.xml FORM 4 X0306 4 2019-12-13 1 0000357097 Fibrocell Science, Inc. FCSC 0001608774 Maslowski John Michael FIBROCELL SCIENCE, INC. 405 EAGLEVIEW BOULEVARD EXTON PA 19341 1 1 0 0 CEO Common Stock 2019-12-13 4 D 0 3164 3 D 0 D Option to Purchase Common Stock 232.5 2019-12-13 4 D 0 908 D 2021-01-14 Common Stock 908.0 0 D Option to Purchase Common Stock 82.35 2019-12-13 4 D 0 1167 D 2023-07-19 Common Stock 1167.0 0 D Option to Purchase Common Stock 74.25 2019-12-13 4 D 0 1334 D 2024-01-17 Common Stock 1334.0 0 D Option to Purchase Common Stock 44.1 2019-12-13 4 D 0 1334 D 2024-05-13 Common Stock 1334.0 0 D Option to Purchase Common Stock 52.95 2019-12-13 4 D 0 6668 D 2025-01-20 Common Stock 6668.0 0 D Option to Purchase Common Stock 34.05 2019-12-13 4 D 0 6667 D 2026-03-01 Common Stock 6667.0 0 D Option to Purchase Common Stock 9.94 2019-12-13 4 D 0 16667 D 2026-12-16 Common Stock 16667.0 0 D Option to Purchase Common Stock 3.45 2019-12-13 4 D 0 20000 D 2028-01-25 Common Stock 20000.0 0 D Option to Purchase Common Stock 1.78 2019-12-13 4 D 0 100000 D 2029-04-12 Common Stock 100000.0 0 D Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the "Merger Agreement"), among Fibrocell Science, Inc. (the "Company"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00. Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. /s/ John M. Maslowski 2019-12-13